Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2022 16:01 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our selective NLRP3 inhibitor, VTX2735, expected in Q2 2022 Announced the...
May 09, 2022 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer

ENCINITAS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
May 05, 2022 16:05 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022

ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that...
March 23, 2022 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our oral, selective NLRP3 inhibitor, VTX2735, expected in Q2 2022 Phase 2 trial of...
March 07, 2022 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new...
December 06, 2021 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

ENCINITAS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new...
November 19, 2021 08:00 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new...
November 17, 2021 16:11 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for...
October 25, 2021 16:58 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ENCINITAS, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients...
October 20, 2021 20:38 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

ENCINITAS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients...